Private Market View

NeuroVice

Cary, NC · Founded 2016 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$1.2M
Last round
Seed Round
May 2025

Key facts

  • It has raised $1.2M across 1 recorded rounds; the latest was Seed Round ($270K) in May 2025.
  • Notable investors include Charles Barkley, William Clayton.
  • NeuroVice has filed 1 Form D with the SEC, most recently Jun 2025 ($270K sold to 5 investors).
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·Post-money valuations for all 1 rounds
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for NeuroVice
Create free account
No card required

Funding rounds

1 rounds
May 2025Seed Round$270KSEC filing

About NeuroVice

Manufacturer of a medical device intended to protect the tongue during seizures. The company's product is a structural and functional instrument that prevents the patient from biting and/or injuring their tongue and from hypersalivation, which can lead to foaming at the mouth, enabling users to get enhanced safety during neurological episodes.

Sector
Healthcare
HQ
Cary, NC, United States
Founded
2016
Employees
3
Ownership
Privately Held (backing)
PA Mark — not yet priced

NeuroVice doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in NeuroVice shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on NeuroVice in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.